Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
Gabrielle H Kingsley, David L Scott Rheumatology Unit, Kings College London, London, UK Background: Psoriatic arthritis is an inflammatory arthritis the primary manifestations of which are locomotor and skin disease. Although a number of guidelines have been published citing strategies for reducing...
Guardado en:
Autores principales: | Kingsley GH, Scott DL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3e07cb14dc294b839190baf332c436ca |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer S, et al.
Publicado: (2015) -
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
por: Chiricozzi A, et al.
Publicado: (2019) -
Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options
por: Haroon M, et al.
Publicado: (2013) -
Quality of life in patients with psoriatic arthritis
por: Kseniya Mikhailovna Koreshkova, et al.
Publicado: (2021) -
Leucine‐rich α‐2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis
por: Yuka Shibata, et al.
Publicado: (2021)